Therapy concepts for thyroid carcinoma

被引：0

作者：

Eilsberger, Friederike ^{[1
,4
]}

Kreissl, Michael C. ^{[2
]}

Luster, Markus ^{[3
]}

Pfestroff, Andreas ^{[1
]}

机构：

[1] Univ Klinikum Marburg, Klin Nukl Med, Marburg, Germany

[2] Univ Klinikum Marburg, Abt Nukl Med, Magdeburg, Germany

[3] Univ Marburg, Nucl Med, Marburg, Germany

[4] Univ Klinikum Marburg, Klin Nukl Med, Baldingerstr 1, D-35043 Marburg, Germany

来源：

LARYNGO-RHINO-OTOLOGIE | 2023年

关键词：

thyroid cancer; Schilddrusenkarzinom; Natrium-Iodid-Symporter; CANCER; I-123;

D O I：

10.1055/a-1861-7379

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

Theranostics via the sodium iodide symporter (NIS) offer a unique option in differentiated thyroid carcinoma. The diagnostic and therapeutic nuclides have similar uptake and kinetics, making the NIS the most important theranostic target in this disease. Radioiodine refractory thyroid carcinomas (RRTC) are characterised by reduced/absent NIS expression, thus eliminating this structure as a theranostic target. Also due to limited therapeutic options, there are approaches to generate new theranostic targets in RRTC, via the expression of somatostatin receptors (SSTR) or the prostate-specific membrane antigen (PSMA), but the current evidence does not yet allow a final evaluation of the prospects of success.

引用

页码：488 / 495

页数：8

共 66 条

[21] Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer:: A phase II clinical trial [J].

Iten, Fabienne ;

Mueller, Beat ;

Schindler, Christian ;

Rochlitz, Christoph ;

Oertli, Daniel ;

Maecke, Helmut R. ;

Mueller-Brand, Jan ;

Walter, Martin A. .

CLINICAL CANCER RESEARCH, 2007, 13 (22) :6696-6702

[22]

IWANO S, 2009, COMP I 123 DIAGNOSTI, V23, P777

[23] Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine [J].

Jaber, Tania ;

Waguespack, Steven G. ;

Cabanillas, Maria E. ;

Elbanan, Mohamed ;

Thinh Vu ;

Dadu, Ramona ;

Sherman, Steven I. ;

Amit, Moran ;

Santos, Elmer B. ;

Zafereo, Mark ;

Busaidy, Naifa L. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (10) :3698-3705

[24]

JIANG H, 2018, 18 F TETRAFLUOROBORA, V8, P3918

[25]

Jois B, 2014, CLIN NUCL MED, V39, P505, DOI 10.1097/RLU.0000000000000429

[26] Expression of prostate-specific membrane antigen in normal and malignant human tissues [J].

Kinoshita, Y ;

Kuratsukuri, K ;

Landas, S ;

Imaida, K ;

Rovito, PM ;

Wang, CY ;

Haas, GP .

WORLD JOURNAL OF SURGERY, 2006, 30 (04) :628-636

[27] RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase [J].

Knauf, JA ;

Kuroda, H ;

Basu, S ;

Fagin, JA .

ONCOGENE, 2003, 22 (28) :4406-4412

[28]

Kreiβl MC., 2019, NUKLEARMEDIZINER, V42, P15

[29]

KRENNING E, 1999, RADIOLABELLED SOMATO, V10, P23

[30]

LAKSHMANAN A, 2015, MODULATION THYROIDAL, V6, P31792

← 1 2 3 4 5 6 7 →